Dr. Min Cui is the Founder and Managing Director of Decheng Capital.
At Decheng Capital, Dr. Cui has been focusing on partnerships with entrepreneurs and building biotechnology and medical technology companies globally. He is currently a board member of Alpine Immune Sciences (NASDAQ: ALPN), Bioheng, EpimAb Biotherapeutics, Harton Therapeutics, ImmPACT Bio, Mammoth Biosciences, Mirvie, and Shape Therapeutics. He previously served on the boards of ARMO BioSciences (acquired by Eli Lilly), China Biologic Products (NASDAQ: CBPO), Cirina (acquired by GRAIL), Cue Health (NASDAQ: HLTH), GeneWEAVE Biosciences (acquired by Roche), GenturaDx (acquired by Luminex), GRAIL (acquired by Illumina), Ion Torrent Systems (acquired by Life Technologies), Sino Medical (688108.CH) and Velos Biopharma (acquired by Merck).
Prior to founding Decheng Capital in 2011, Dr. Cui spent 5 years at Bay City Capital, a leading international life science venture capital firm in San Francisco. He was previously Director of Strategic Investment for the Southern Research Institute, an organization that discovered and developed six anti-cancer drugs that approved by the US Food and Drug Administration. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals, where he led efforts in the discovery and development of several key technologies in the fields of oncology, cardiology, infectious and inflammatory diseases.
Dr. Cui received his PhD in Cancer Biology from Stanford University and his BS and MS in Molecular Biology from Peking University. Dr. Cui is currently a board of trustee at Western University of Health Sciences.